Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

A novel treatment algorithm for pulmonary arterial hypertension is launched today in new pulmonary hypertension guidelines from the European Society of Cardiology and European Respiratory Society. [More]
Optimal aerobic exercise training may benefit patients with pulmonary arterial hypertension

Optimal aerobic exercise training may benefit patients with pulmonary arterial hypertension

A physical therapy researcher with the IU School of Health and Rehabilitation Services at Indiana University-Purdue University Indianapolis has been awarded a $465,000 National Institutes of Health grant to optimize aerobic exercise training for patients with pulmonary arterial hypertension, a goal data suggests could reduce morbidity and mortality among those with the disease. [More]
Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015. [More]
Novel treatment target found for RV failure in PAH

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension. [More]
Low GLSRV heralds adverse outcomes in PAH patients

Low GLSRV heralds adverse outcomes in PAH patients

Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators. [More]
Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis patients with pulmonary arterial hypertension, but they do not predict survival, US research shows. [More]
Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2015. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP). [More]
Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Stress Doppler echocardiography ‘reliable’ for early PAH detection in systemic sclerosis

Stress Doppler echocardiography ‘reliable’ for early PAH detection in systemic sclerosis

Researchers recommend performing echocardiography at rest and during exercise to screen for pulmonary arterial hypertension in patients with systemic sclerosis. [More]
Oral PAH treatments stave off clinical decline

Oral PAH treatments stave off clinical decline

Oral treatments for pulmonary arterial hypertension reduce patients’ risk of clinical worsening but have little effect on survival, say the authors of a meta-analysis. [More]

Prognosis still gloomy for idiopathic PAH

Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies. [More]
PAH diagnosis delayed for adult congenital heart disease patients

PAH diagnosis delayed for adult congenital heart disease patients

Pulmonary arterial hypertension is often not diagnosed in adult patients with congenital heart disease until 6 years or more after their symptoms first appear, research shows. [More]
Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Mayo Clinic in Jacksonville, Fla., and United Therapeutics Corporation today announced a collaboration to build and operate a lung restoration center on the Mayo campus. The goal is to significantly increase the volume of lungs for transplantation by preserving and restoring selected marginal donor lungs, making them viable for transplantation. The restored lungs will be made available to patients at Mayo Clinic and other transplant centers throughout the United States. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Noninvasive findings reduce catheterisation need in suspected PAH

Noninvasive findings reduce catheterisation need in suspected PAH

Research shows that a risk score based on noninvasive measures can identify left heart failure in a “substantial percentage” of patients with suspected pulmonary arterial hypertension, reducing the need for right heart catheterisation. [More]

Early intensive epoprostenol yields best haemodynamic outcomes in PAH

Patients with pulmonary arterial hypertension achieve greater improvements in right heart haemodynamics if epoprostenol is given rapidly and at a high dose, research suggests. [More]
Meta-analysis supports ambrisentan efficacy

Meta-analysis supports ambrisentan efficacy

A meta-analysis supports the efficacy of ambrisentan in patients with pulmonary arterial hypertension. [More]
Advertisement
Advertisement